Analysts expect that Acer Therapeutics Inc (NASDAQ:ACER) will report ($0.55) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Acer Therapeutics’ earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.57). Acer Therapeutics posted earnings per share of ($0.93) during the same quarter last year, which indicates a positive year over year growth rate of 40.9%. The company is scheduled to issue its next earnings results on Monday, August 13th.

According to Zacks, analysts expect that Acer Therapeutics will report full-year earnings of ($2.29) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.09). For the next financial year, analysts anticipate that the business will report earnings of ($2.07) per share, with EPS estimates ranging from ($2.82) to ($1.13). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Acer Therapeutics.

Acer Therapeutics (NASDAQ:ACER) last issued its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.16.

Several brokerages recently commented on ACER. Roth Capital began coverage on shares of Acer Therapeutics in a research report on Monday, February 26th. They issued a “buy” rating and a $70.00 price target for the company. HC Wainwright set a $50.00 price target on shares of Acer Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 22nd. William Blair began coverage on shares of Acer Therapeutics in a research report on Friday, February 16th. They issued an “outperform” rating for the company. ValuEngine upgraded shares of Acer Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Finally, Zacks Investment Research upgraded shares of Acer Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $47.33.

A number of hedge funds have recently added to or reduced their stakes in ACER. Perceptive Advisors LLC purchased a new stake in Acer Therapeutics in the 4th quarter worth approximately $2,091,000. J. Goldman & Co LP purchased a new stake in Acer Therapeutics in the 4th quarter worth approximately $1,496,000. Stonepine Capital Management LLC purchased a new stake in Acer Therapeutics in the 4th quarter worth approximately $1,385,000. Heartland Advisors Inc. purchased a new stake in Acer Therapeutics in the 1st quarter worth approximately $1,071,000. Finally, Neuberger Berman Group LLC purchased a new stake in Acer Therapeutics in the 1st quarter worth approximately $385,000. Institutional investors own 8.17% of the company’s stock.

Shares of NASDAQ:ACER traded down $0.55 during mid-day trading on Friday, hitting $19.31. The stock had a trading volume of 106 shares, compared to its average volume of 21,560. The company has a market cap of $142.30 million, a PE ratio of -5.08 and a beta of 2.31. Acer Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63.

Acer Therapeutics Company Profile

Acer Therapeutics Inc develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Get a free copy of the Zacks research report on Acer Therapeutics (ACER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.